Clinical application of bevacizumab as adjuvant chemotherapy for non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2025.02.015

Abstract

Abstract:

Objective

To analyze the efficacy and safety of Bevacizumab injection （Avastin）combined with standardized chemotherapy in elderly patients with non-small cell lung cancer （NSCLC）.

Methods

A total of 74 elderly NSCLC patients admitted to our hospital from January 2017 to December 2022 were enrolled，divided into two groups based on treatment methods： 34 patients received a combination of paclitaxel and cisplatin chemotherapy （TP） as the control group，and 40 patients received a combination of TP and bevacizumab as the observation group. The treatment course lasted six cycles （18 weeks）. Clinical efficacy，tumor marker levels，immune function，overall survival rate （OS），progression-free survival （progression-free survival，PFS），and treatment-related adverse events （AE） were analyzed between the two groups.

Results

The total effective rate in the observation group was 31 cases（77.50%），while that in the control group was 20 cases（58.82%）. The total effective rate of the observation group was higher than that of the control group there was no significant difference between two groups. After treatment，the carcinoembryonic antigen（carcinoembryonic antigen，CEA） level in the observation group decreased to 16. 75 ± 2. 45） ng/ml，carbohydrate antigen 125 （carbohydrate antigen 125，CA125）（35.97±4.46） ng/ml，cytokeratin 19 fragment（cytokeratin，CY211）（15.45±2.43） U/ml； lower than the control group CEA （20.93±3.16） ng/ml，CA125（50.11±6.58） ng/ml，CY211 （20.35±3.26） U/ml； in the observation group after treatment，immune function CD3⁺（49.16±4.32），CD4⁺（30.31±3.41），CD8⁺（32.56±4.30），natural killer cells （NK）（21.02±3.06）were better than the control group （45.40±4.12），（26.68±3.02），（35.79±4.69），（17.69±2.21）（P＜0.05）.During the follow-up period of the observation group，11 cases died，and an average OS of 20.34 months（18.70，21.96）； 16 deaths in the control group，average OS 15.03 months （12.83，17.37），the difference between the two groups was statistically significant （χ²=4.992，P=0.025）. The adverse drug reaction rate in the observation group was 20.00%，in the control group was 23.53%，with no statistical significance （P ＞0.05）.

Conclusion

Bevacizumab injection （Avastin） combined with standardized chemotherapy can improve clinical efficacy in elderly NSCLC patients，extend progression-free survival and overall survival，without increasing the incidence of adverse reactions，demonstrating good clinical efficacy and safety in the treatment of elderly NSCLC.

Key words: Bevacizumab, Standardized chemotherapy, Non-small cell lung cancer, Clinical efficacy

Lili Zhang, Feng Xu, Xunpeng Xie, Xueliang Zhang, Honghua Ji, Wenfei Ji. Clinical application of bevacizumab as adjuvant chemotherapy for non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(02): 284-288.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2025.02.015

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2025/V18/I02/284

Figures/Tables 2

References 30

1	Lee J，Kim JH，Kim CW. CyberKnife-based stereotactic radiosurgery or fractionated stereotactic radiotherapy in older patients with brain metastases from non-small cell lung cancer.［J］. ROJ，2023，41（4）： 258-266.
2	王洪武，金发光. 晚期非小细胞肺癌多域整合治疗策略［J/CD］. 中华肺部疾病杂志（电子版），2022，15（4）： 457-461.
3	Ruchira M，Sajjad AB，Bradley CM，et al. Real-world survival of first-line immune checkpoint inhibitor treatment versus chemotherapy in older patients with non-small-cell lung cancer and synchronous brain metastases［J］. JCO Oncol Pract，2023，19（11）： 1009-1019.
4	Nicholas JB，Patel JD，Wakelee HA，et al. Phase Ⅱrandomized trial of carboplatin，pemetrexed，and bevacizumab with and without atezolizumab in stage Ⅳnonsquamous non-small-cell lung cancer patients who harbor a sensitizing EGFR mutation or have never smoked［J］. Clin Lung Cancer，2023，24（7）： e242-e246.
5	Fan Z，Di H，Tao L，et al. Anti-PD-1 therapy plus chemotherapy and/or bevacizumab as second line or later treatment for patients with advanced non-small cell lung cancer.［J］. J Cancer，2020，11（3）： 741-749.
6	陈国群，蔡姣迪. 2022 年美国国立综合癌症网络（NCCN）《非小细胞肺癌临床诊疗指南》（第4 版及第5 版）解读［J］. 诊断学理论与实践，2023，22（1）： 8-13.
7	Mustachio LM，Roszik J. Current targeted therapies for the fight against non-small cell lung cancer［J］. Pharmaceuticals （Basel），2020，13（11）： 374.
8	Liang HY，Liu Do，Wang H，et al. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients［J］. J Geriatr Cardiol，2023，20（10）： 737-747.
9	王朝，韩雪，张爱霞. LIPI 评分对PD-1/PD-L1 抑制剂治疗非小细胞肺癌效果与预后的价值分析［J］. 中国现代医学杂志，2023，33（6）： 55-60.
10	吴冠锦，刘祎，焦丽静，等. 非小细胞肺癌表皮生长因子受体酪氨酸酶抑制药耐药通路抑制剂的临床应用现状［J］. 中国临床药理学杂志，2023，39（6）： 893-897.
11	Ko R，Mouri A，Kisohara A，et al. 1292MO A phase Ⅱstudy of daily carboplatin plus irradiation followed by durvalumab for unresectable Ⅲnon-small cell lung cancer patients with PS 2 or elderly （≧75 years）： NEJ039A［J］. Ann Oncol，2023，34（S2）：S745-S746.
12	贾琎蕊，李晓红，胡滨. 老年非小细胞肺癌患者术后生活质量的纵向研究［J］. 中华老年多器官疾病杂志，2024，23（6）：416-420.
13	Zeeshan T，McKenna B. A durable response to osimertinib in an elderly patient with EGFR T790M positive metastatic non-small-cell lung cancer after progression on erlotinib［J］. Am J Ther，2023，30（5）： e463-e465.
14	张亚玲，刘单，邓述恺. 贝伐珠单抗通过调控PI3K/AKT 信号通路下调肺腺癌H1299 细胞PD-L1 表达［J］. 中国免疫学杂志，2023，39（1）： 104-108.
15	孙晋瑞，何玥，吴玉梅. 贝伐珠单抗在晚期及复发性卵巢癌治疗中的研究进展［J］. 实用妇产科杂志，2024，40（6）： 464-468.
16	Marrone KA，Zhou X，Forde PM，et al. A randomized phase Ⅱstudy of metformin plus paclitaxel/carboplatin/bevacizumab in patients with chemotherapy-naïve advanced or metastatic nonsquamous non-small cell lung cancer［J］. Oncologist，2018，23（7）： 859-865.
17	Zhang F，Huang D，Li T，et al. Anti-PD-1 therapy plus chemotherapy and/or bevacizumab as second line or later treatment for patients with advanced non-small cell lung cancer ［J］. J Cancer，2020，11（3）： 741-749.
18	侯俊杰，米旭光，李孝男，等. 贝伐珠单抗联合紫杉醇治疗非小细胞肺癌过程中并发支气管胸膜瘘1 例报告及文献复习［J］.吉林大学学报（医学版），2022，48（2）： 513-517.
19	陈海韬，杨森森，邓为上，等. 贝伐珠单抗生物类似药和原研药治疗非小细胞肺癌有效性、安全性和免疫原性的Meta 分析［J］.中国药房，2022，33（8）： 1003-1008.
20	王晨，李艳，管燕，等. EGFR-TKIs 治疗失败非小细胞肺癌患者采用免疫联合化疗及贝伐珠单抗治疗的疗效及影响因素［J］. 中华医学杂志，2023，103（16）： 1210-1216.
21	Maciej L，Josiane O，PierreYves B，et al. Safety and efficacy of two-drug combination in elderly patients with locally advanced nonsmall cell lung cancer and validation of the Charlson Index as a predictor of survival.［J］. J Thorac Dis，2023，15（7）： 3764-3775.
22	Toshio K，Eiki I，Daijiro H，et al. Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer［J］. Resp Investig，2023，61（5）： 643-650.
23	杨光霞，程云涛，刘琳琳，等. 阿美替尼片联合贝伐珠单抗注射液治疗表皮生长因子受体突变的晚期非小细胞肺癌患者的临床研究［J］. 中国临床药理学杂志，2023，39（11）： 1528-1532.
24	顾艳斐，田笑如，王若天，等. 奥希替尼联合贝伐珠单抗在获得性EGFRT790M 突变晚期非小细胞肺癌的疗效分析［J］. 中国肺癌杂志，2022，25（12）： 843-851.
25	Lipin L，Runze L，Yue P，et al. Surgery vs. radiotherapy in a population-based cohort of elderly patients with early-stage small-cell lung cancer： an IPTW propensity-score analysis［J］. J Thorac Dis，2023，15（5）： 2769-2778.
26	Qin Y，Ma FY，Zhang Z，et al. Vascular endothelial growth factor pathway's influence on bevacizumab efficacy in metastatic colorectal cancer treatment［J］. World J Gastrointest Oncol，2024，16（11）：4514-4517.
27	Gao Y，Liu Z，Liu Y. Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects［J］. World J Surg Oncol，2021，19（1）： 280.
28	Zhang S，Mi Y，Ye T，et al. Carbohydrates and ginsenosides in shenmai injection jointly improve hematopoietic function during chemotherapy-induced myelosuppression in mice［J］. Chin Med，2022，17（1）： 124.
29	Fang S，Cao H，Liu J，et al. Antitumor effects of IOX1 combined with bevacizumab-induced apoptosis and immunity on colorectal cancer cells［J］. Int Immunopharmacol，2024，141： 112896.
30	张佳慧，郭其森，张初峰，等. EGFR 20 外显子插入突变晚期NSCLC 化疗联合免疫治疗对比联合贝伐珠单抗临床分析［J］.中华肿瘤防治杂志，2022，29（11）： 828-833.

组　别	例数	CEA（ng/ ml）		CA125（ng/ ml）		CY211（U/ ml）
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	26.75±3.48	16.75±2.45^a	60.78±7.21	35.97±4.46^a	34.10±4.52	15.45±2.43^a
对照组	34	27.24±3.63	20.93±3.16^a	61.21±7.42	50.11±6.58^a	34.52±4.73	20.35±3.26^a
t 值		0.592	6.405	0.252	10.995	0.390	7.395
P值		0.556	0.050	0.802	0.050	0.698	0.050

组　别	例数	CEA（ng/ ml）		CA125（ng/ ml）		CY211（U/ ml）
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	26.75±3.48	16.75±2.45^a	60.78±7.21	35.97±4.46^a	34.10±4.52	15.45±2.43^a
对照组	34	27.24±3.63	20.93±3.16^a	61.21±7.42	50.11±6.58^a	34.52±4.73	20.35±3.26^a
t 值		0.592	6.405	0.252	10.995	0.390	7.395
P值		0.556	0.050	0.802	0.050	0.698	0.050

组　别	例数	CD3⁺		CD4⁺		CD8⁺		NK
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	51.72±5.54	49.16±4.32^a	32.49±4.34	30.31±3.41^a	30.42±4.12	32.56±4.30^a	23.11±3.44	21.02±3.06^a
对照组	34	51.35±5.31	45.40±4.12^a	33.12±4.59	26.68±3.02^a	30.61±4.26	35.79±4.69^a	23.35±3.50	17.69±2.21^a
t 值		0.292	3.811	0.606	4.807	0.195	3.089	0.297	5.280
P值		0.771	0.050	0.546	0.050	0.846	0.050	0.768	0.050

组　别	例数	CD3⁺		CD4⁺		CD8⁺		NK
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	51.72±5.54	49.16±4.32^a	32.49±4.34	30.31±3.41^a	30.42±4.12	32.56±4.30^a	23.11±3.44	21.02±3.06^a
对照组	34	51.35±5.31	45.40±4.12^a	33.12±4.59	26.68±3.02^a	30.61±4.26	35.79±4.69^a	23.35±3.50	17.69±2.21^a
t 值		0.292	3.811	0.606	4.807	0.195	3.089	0.297	5.280
P值		0.771	0.050	0.546	0.050	0.846	0.050	0.768	0.050

[1]	Jie Wang, Quan Yuan, Yueqi Wang, Jiajun Qiao, Chunli Tan, Zhongyuan Xia, Shouyao Liu. Observation on the application effect and safety of ulcer oil in the treatment of diabetic foot ulcer [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(06): 480-484.
[2]	Xia Wang, Gaofeng Yuan, Guangli Bian, Huijun Jia, Guang Han, Zhen Song, Zhugen Cao. Clinical significance of ctDNA in predicting recurrence risk of non-small cell lung cancer after adjuvant chemotherapy [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(02): 266-272.
[3]	Zhaolei You, Xiaoliang Jing, Liang Zong, Qingchao Sun, Desheng Li, Liwei Zhang. Analysis of therapeutic efficacy of advanced non-small cell lung cancer treated with Nituzumab versus Anlotinib radiochemotherapy [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(02): 231-235.
[4]	Xinchao Cao, Yongfeng Ma, Ping Ma, Lijun He, Rongjing Xie. Analysis of programmed death ligand 1 expression in non-small cell lung cancer during perioperative period [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(02): 251-255.
[5]	Qiushuang Ma, Minghan Yang, Yaolin Wang, Yingying Lan, Ziteng Liu, Jingku Zhang. Expression and clinical significance of serum exosomal human microRNA-195-5p in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(02): 261-265.
[6]	Qiao Lv, Qian Min, Lu Jiang, Qian Chen, Jin Peng, Qian Dai. Effect of overexpression of KLF7 on proliferation and apoptosis of human non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(01): 1-7.
[7]	Kejia Yang, Qi Sun, Weifeng Qu, Yuan Weng, Qichen Cui, Jinyou Li. Clinical application of Flex-3D thoracoscopic lobectomy in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(01): 62-67.
[8]	Yan Liu, Peiyan Zhao, Lin Tian, Heran Cui, Na Di, Hui Li, Ying Cheng. Anti-tumor activity and mechanism of the novel OX40 antibody agonist in humanized mouse NSCLC model [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(06): 901-906.
[9]	Pengfei Xie, Jia Chen, Xiaodong Zhang, Chunrong Zhang, Feng Xu. Clinical analysis of lobar emphysema ratio for predicting persistent air leakage after video-assisted thoracoscopic lobectomy in NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(06): 907-912.
[10]	Qian Zheng, Yan Xu, Yanlu Xiong, Yang Liu, Yongfu Ma. Comparison of anatomical subsegment-based precise lung resection versus lobectomy in the treatment of stage IA1-IA2 lung adenocarcinoma [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2025, 18(01): 32-37.
[11]	Jing Chen, Tianqi Liu, Lili Wang, Liquan Yin. Extracorporeal shock wave therapy for muscle spasm after stroke：a Meta-analysis [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2024, 14(06): 334-340.
[12]	Jiaojiao Li, Xue Hui, Meirong Yang, Hongjun Zhou. Study on the therapeutic effect of acupoint electrical stimulation combined with traditional Chinese medicine navel hot ironing as an adjuvant therapy for post-stroke constipation patients [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 69-72.
[13]	Junling Han, Gang Wang, Liying Ma, Ying Lian, Hui Xu. Study on the therapeutic effect of vitamin D combined with povidone bromide tablets on diarrhea type patients with irritable bowel syndrome and its impact on intestinal barrier function indicators [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 560-564.
[14]	Jun Zhou, Wen Wang, Yinshan Zang, Yan Xu. Predictors of clinical efficacy of adalimumab in treatment of rheumatoid arthritis [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(01): 41-47.
[15]	Danwen Zhao, Dandan Liu, Wendeng Li, Ranran Kong, Shiyuan Liu. Impact of adjuvant chemotherapy on survival for patients with completely resected stage T2bN0M0 non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2025, 12(01): 12-23.

Please choose a citation manager

Content to export